Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
VERSED (midazolam) is an oral syrup small-molecule sedative approved in 1998 for use in shoulder surgery and other procedural sedation. It works as a benzodiazepine central nervous system depressant. The drug is indicated for preoperative anxiolysis and sedation in surgical patients.
Approaching loss of exclusivity signals a transition phase; brand teams are likely focused on lifecycle extension, generic defense, or portfolio transition strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Worked on VERSED at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Roche is hiring 3 roles related to this product
Working on VERSED offers limited career growth opportunity given the LOE-approaching lifecycle stage and zero linked job openings. Roles on this product are typically focused on defensive commercialization, generic transition management, and market-share preservation rather than innovation or expansion.